Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nicolás Ms, Gálvez"'
Autor:
Martín Dib, Nicole Le Corre, Catalina Ortiz, Daniel García, Marcela Ferrés, Constanza Martinez-Valdebenito, Cinthya Ruiz-Tagle, María José Ojeda, Manuel A. Espinoza, Aquiles Jara, Juan Pablo Arab, Ricardo Rabagliati, Cecilia Vizcaya, María Elena Ceballos, Mauricio Sarmiento, Sebastián Mondaca, Macarena Viñuela, Antonia Pastore, Vania Szwarcfiter, Elizabeth Galdames, Aldo Barrera, Pablo Castro, Nicolás MS Gálvez, Jorge A. Soto, Susan M. Bueno, Alexis M. Kalergis, Bruno Nervi, M. Elvira Balcells
Publikováno v:
The Lancet Regional Health. Americas, Vol 16, Iss , Pp 100371- (2022)
Summary: Background: Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mR
Externí odkaz:
https://doaj.org/article/c59988b4c6e44e479dc4cb836721da24
Autor:
Nicolás MS Gálvez, Gaspar A Pacheco, Bárbara M Schultz, Felipe Melo-González, Jorge A Soto, Luisa F Duarte, Liliana A González, Daniela Rivera-Pérez, Mariana Ríos, Roslye V Berrios, Yaneisi Vázquez, Daniela Moreno-Tapia, Omar P Vallejos, Catalina A Andrade, Guillermo Hoppe-Elsholz, Carolina Iturriaga, Marcela Urzua, María S Navarrete, Álvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Mónica L Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alba Grifoni, Alessandro Sette, Gang Zeng, Weining Meng, CoronaVacCL03 Study Group, José V González-Aramundiz, Marina Johnson, David Goldblatt, Pablo A González, Katia Abarca, Susan M Bueno, Alexis M Kalergis
Publikováno v:
eLife, Vol 11 (2022)
Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine approved for eme
Externí odkaz:
https://doaj.org/article/ac762f639ff7488791e3508152fce059
Autor:
Bárbara M, Schultz, Felipe, Melo-González, Luisa F, Duarte, Nicolás Ms, Gálvez, Gaspar A, Pacheco, Jorge A, Soto, Roslye V, Berríos-Rojas, Liliana A, González, Daniela, Moreno-Tapia, Daniela, Rivera-Pérez, Mariana, Ríos, Yaneisi, Vázquez, Guillermo, Hoppe-Elsholz, Omar P, Vallejos, Carolina, Iturriaga, Marcela, Urzua, María S, Navarrete, Álvaro, Rojas, Rodrigo, Fasce, Jorge, Fernández, Judith, Mora, Eugenio, Ramírez, Aracelly, Gaete-Argel, Mónica, Acevedo, Fernando, Valiente-Echeverría, Ricardo, Soto-Rifo, Daniela, Weiskopf, Alba, Grifoni, Alessandro, Sette, Gang, Zeng, Weining, Meng, José V, González-Aramundiz, Pablo A, González, Katia, Abarca, Alexis M, Kalergis, Susan M, Bueno
Publikováno v:
medRxiv : the preprint server for health sciences.
BackgroundCoronaVac®is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- and four-weeks after two doses of CoronaVac®, but th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5dcd784221a536d2fd34dfe24d2529
https://pubmed.ncbi.nlm.nih.gov/35946814
https://pubmed.ncbi.nlm.nih.gov/35946814